NasdaqGS:FTRELife Sciences
Fortrea (FTRE) Partnership With SCTbio: Is the Rebound Justified by Its Current Valuation?
SCTbio’s new collaboration with Fortrea Holdings (FTRE) is turning heads, as investors weigh how this advanced therapies partnership could reshape development timelines, costs, and Fortrea’s role across the crowded cell and gene therapy pipeline.
See our latest analysis for Fortrea Holdings.
That backdrop helps explain why the stock’s 1 month share price return of 54.27 percent and 3 month share price return of 55.77 percent look like momentum is rebuilding, even though the year to date share...